Scopus Biopharma, Inc.

As of June 30, 2023, Scopus Biopharma, Inc. carries a market capitalization of 2.27M, placing it among publicly traded companies globally. Its enterprise value stands at 857,663.26, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Scopus Biopharma, Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2023, Scopus Biopharma, Inc. has 42.08M shares outstanding.

These figures are as of June 30, 2023.

As of June 30, 2023, Scopus Biopharma, Inc. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2023. Return on assets (ROA) is negative at -801.26, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 12.00, a quick read on workforce productivity versus industry peers.

As of the close on October 15, 2026, Scopus Biopharma, Inc.'s stock has gained approximately 33.33% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended June 30, 2023, Scopus Biopharma, Inc. generated - - in revenue and converted that into -8.70M in net income, yielding earnings per share of -0.33. EBITDA reached -9.34M, while operating income came in at -9.34M.

These figures are as of June 30, 2023. Total book value stands at -9.45M, with working capital of -10.51M providing operational flexibility.

Scopus Biopharma, Inc. produced -3.04M in operating cash flow over the twelve months ended June 30, 2023. After subtracting - - in capital expenditures, free cash flow totaled -3.04M - equivalent to -0.11 per share.

These figures cover the twelve months ended June 30, 2023. Free cash flow yield is negative at -200.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -97.54, meaning Scopus Biopharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2023, Scopus Biopharma, Inc. has an Altman Z-Score of -250.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.